What does this research mean for the field?

Mirabegron is well tolerated in patients with overactive bladder regardless of the presence of cardiovascular comorbidities. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 22, 2026European Urology Focus1 citationsOpen Access

View Full Paper

Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials

ALAmy LockefeerAstellas Pharma (United States)ASArianne SchildAstellas Pharma (United States)SASwapneel AnaokarAstellas Pharma (Japan)

Key Points

To evaluate the efficacy and safety of mirabegron in patients with overactive bladder and cardiovascular comorbidities.
Post hoc analysis of randomised trials
Comparison of mirabegron efficacy between patients with and without cardiovascular comorbidities
Assessment of cardiac treatment-emergent adverse events (TEAEs)
No significant differences in efficacy for mirabegron between groups
Low prevalence of cardiac TEAEs observed
Mirabegron was well tolerated in both patient groups

Abstract

No significant differences in mirabegron efficacy were noted between groups with OAB with and without CRC. Low prevalence of cardiac TEAEs was noted, which indicates that mirabegron was well tolerated in both groups.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials

Key Points

Abstract

Cite This Study

Also Consider

Also Consider